RxDoctor Payments Data

Jayme Heim, NP

Family · Grandville, MINPI 1992912836

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 23.1%. Among family clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$663,028in general payments, 2019–2025

Across 2,135 payments — averaging $310.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$153K
  • Lilly USA, LLC$75K
  • UCB, Inc.$59K
  • Incyte Corporation$47K
  • Arcutis Biotherapeutics, Inc.$44K
  • Janssen Scientific Affairs, LLC$39K
  • plus $246K from 31 others

What the payments were for

  • Consulting fees$167,11725%
  • Speaking & faculty fees$354,31153%
  • Travel & lodging$99,70315%
  • Food & beverage$40,9216%
  • Education$9760%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$663,028 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$200,428
Medicare patients
70
Services billed
1,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab56$468,184
SkyriziRisankizumab-Rzaa21$414,843
TremfyaGuselkumab32$403,103
Cosentyx Sensoready (2 Pens)Secukinumab48$403,055
Skyrizi PenRisankizumab-Rzaa16$325,985
StelaraUstekinumab13$224,615
Dupixent SyringeDupilumab39$174,695
Dupixent PenDupilumab44$157,984
OtezlaApremilast17$80,242
Clobetasol Propionate233$7,338
MethotrexateMethotrexate Sodium141$3,316
Betamethasone Dipropionate35$1,750
Hydroxyzine Hcl179$1,667
Triamcinolone Acetonide98$1,615
Fluocinonide28$1,561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya, Stelara$153,278$627,71945 claims
AbbVieSkyrizi$7,652$414,84321 claims
AmgenOtezla$24,509$80,24217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Grandville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →